2ONE Labs Wins Preliminary Injunction in Trademark Dispute

Jan.03

2ONE Labs and Performance Plus Marketing pay $1M bond for preliminary injunction in trademark dispute with ZONE.

According to Ein Presswire on January 2, the American nicotine pouch brand 2ONE Labs and distributor Performance Plus Marketing have paid a $1 million bond to the court in order to secure a preliminary injunction in their trademark dispute with the tobacco brand ZONE.

Vincent Schuman, CEO of 2ONE Labs, emphasized that...

The deposit reflects our commitment to protecting the intellectual property of 2ONE, ensuring the brand's unrestricted expansion in the market without any hindrance from trademark infringers.

Vincent pointed out that the guarantee was made in accordance with a court order and is a crucial step in protecting the company's brand. It is intended to cover any potential losses that may occur if the injunction is overturned. Such legal requirements are common in trademark disputes, and the guarantee amount is much lower than the $50 million initially proposed by Imperial.

2ONE Labs and Performance Plus Marketing remain optimistic during this litigation phase, anticipating a favorable outcome to protect 2ONE's extensive trademark rights in the nicotine pouch product field.

On December 23rd, the American nicotine pouch brand 2ONE Labs announced on its official website that the brand had obtained a favorable preliminary injunction (PI) ruling in a trademark dispute with distributor Performance Plus Marketing over the Empire Tobacco brand ZONE. According to a court order dated December 20, 2024, ZONE nicotine pouches are prohibited from being shipped to trade partners in the United States. (Related reading: 2ONE wins preliminary injunction, Empire Tobacco's ZONE nicotine pouch sales in the U.S. restricted)

References:

[1] [Corrected Release] 2ONE® Secures Preliminary Injunction Bond in Trademark Dispute Against Imperial's Zone Products

Also Read:

[1] 2ONE Labs Prevails in Trademark Dispute against IMB Zone Brand

[2] 2ONE Labs Announces PMTA Submission Update, Nicotine Pouch Products Receive FDA 'Acceptance' Again

[3] U.S. nicotine pouch brand 2ONE Labs says 2ONE® gains FDA “approval”

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Lawmakers Seek to Empower HHS to Destroy Counterfeit Chinese Tobacco Products

Bipartisan members of the U.S. Congress have introduced the “Ensuring the Necessary Destruction of Illicit Chinese Tobacco Act” (END Act), seeking to amend the Federal Food, Drug, and Cosmetic Act to authorize the Department of Health and Human Services (HHS) to directly destroy adulterated, misbranded, or counterfeit imported tobacco products.Major tobacco companies, including Altria, along with several public health organizations, have announced their support for the bill.

Nov.11 by 2FIRSTS.ai

Philip Morris and R.J. Reynolds Face Trial Over Woman’s Lung Cancer Death in Massachusetts

According to Law360, the family of Maria Petruzziello has taken Philip Morris and R.J. Reynolds to trial in Massachusetts, alleging the companies are responsible for her 2019 lung cancer death after decades of smoking. Plaintiffs argue her experience mirrors many smokers, while the defense points to her years-long cessation and personal choice.

Dec.03 by 2FIRSTS.ai

Italian anti-trust agency investigates PMI's marketing of smoke-free products, company denies wrongdoing

Italian anti-trust agency investigates Philip Morris International's promotion of smoke-free products, questioning potentially misleading language.

Oct.16 by 2FIRSTS.ai

R.J. Reynolds Seeks Dismissal of “Carbon Neutral” Lawsuit over Vuse E-Cigarette Claims

R.J. Reynolds Vapor Co. has moved to dismiss a class-action lawsuit alleging false “carbon neutral” claims for its Vuse e-cigarettes, arguing its statements were based on independent certifications from Verra and Vertis, not misleading consumers.